Details of the Drug Combination

General Information of Drug Combination (ID: DC8VT0U)

Drug Combination Name
Imatinib Ifosfamide
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Imatinib   DM7RJXL Ifosfamide   DMCT3I8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OVCAR3
Zero Interaction Potency (ZIP) Score: 5.36
Bliss Independence Score: 8.22
Loewe Additivity Score: 3.72
LHighest Single Agent (HSA) Score: 2.95

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Imatinib
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [2]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [3]
Choroidal neovascularization 9B76 Approved [3]
Chronic eosinophilic leukemia N.A. Approved [3]
Chronic myelogenous leukaemia 2A20.0 Approved [4]
Chronic myeloid leukaemia 2A20 Approved [5]
Dermatofibrosarcoma protuberans N.A. Approved [3]
Gastrointestinal stromal tumour 2B5B Approved [3]
Leukemia N.A. Approved [3]
Malignant peripheral nerve sheath tumor N.A. Approved [3]
Myeloproliferative neoplasm 2A20 Approved [3]
Pulmonary hypertension BB01 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Intestinal cancer 2C0Z Phase 3 [4]
Lung cancer 2C25.0 Phase 2 [4]
Idiopathic hypereosinophilic syndrome N.A. Investigative [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [7]
Scleroderma 4A42 Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [7]
Systemic mastocytosis 2A21.0 Investigative [8]
Imatinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mcl-1 messenger RNA (MCL-1 mRNA) TTN6ORK MCL1_HUMAN . [8]
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [14]
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Inhibitor [14]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Inhibitor [14]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Imatinib Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [17]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [18]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [19]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Imatinib Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [20]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [21]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [23]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [24]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [25]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [26]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Imatinib Interacts with 95 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Methylation [27]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [27]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Methylation [27]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Methylation [27]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [28]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [28]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Decreases Expression [29]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Expression [29]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Decreases Expression [29]
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHB) OT2NHE5E ODPB_HUMAN Decreases Expression [29]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [29]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [29]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Expression [29]
Eukaryotic translation initiation factor 4B (EIF4B) OTE8TXA8 IF4B_HUMAN Decreases Expression [29]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Decreases Expression [29]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [29]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [29]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [29]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [29]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [29]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Expression [29]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [30]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [31]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [32]
Autophagy-related protein 13 (ATG13) OTYMHNEJ ATG13_HUMAN Increases Phosphorylation [11]
Platelet-derived growth factor subunit B (PDGFB) OTMFMFC3 PDGFB_HUMAN Decreases Expression [33]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [34]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [35]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Increases Expression [36]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [37]
Heat shock protein beta-1 (HSPB1) OTHFZ8ED HSPB1_HUMAN Increases Expression [32]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [38]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [32]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [39]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [34]
Cathepsin B (CTSB) OTP9G5QB CATB_HUMAN Increases Expression [11]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Phosphorylation [40]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM) OT1QY9JM PFKAM_HUMAN Decreases Expression [41]
Platelet-derived growth factor receptor beta (PDGFRB) OTYSNK9Q PGFRB_HUMAN Decreases Expression [33]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [42]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [32]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [43]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Decreases Expression [37]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [13]
Lysosome-associated membrane glycoprotein 1 (LAMP1) OTYE92QY LAMP1_HUMAN Increases Expression [11]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases Expression [32]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Increases Expression [36]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [44]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [45]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Expression [33]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [32]
Histidine decarboxylase (HDC) OT4WA5YQ DCHS_HUMAN Decreases Expression [46]
Transcription factor EB (TFEB) OTJUJJQY TFEB_HUMAN Affects Localization [11]
Fibroblast growth factor receptor 3 (FGFR3) OTSAXDIL FGFR3_HUMAN Decreases Expression [47]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [32]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [48]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Increases Expression [32]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [34]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [32]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [39]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [39]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Cleavage [35]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [49]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [50]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [51]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [11]
Hexokinase-2 (HK2) OTC0GCQO HXK2_HUMAN Decreases Expression [41]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [11]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Expression [32]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [49]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [43]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [52]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [42]
Forkhead box protein M1 (FOXM1) OT5887KR FOXM1_HUMAN Decreases Expression [49]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [53]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [11]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Increases Expression [11]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [54]
NGFI-A-binding protein 2 (NAB2) OTG4BDF3 NAB2_HUMAN Increases Expression [32]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [55]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [38]
TRAF family member-associated NF-kappa-B activator (TANK) OTZSGFIK TANK_HUMAN Increases Expression [32]
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) OTZM6MHU NLRP3_HUMAN Increases Expression [35]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Increases Activity [54]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [56]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [11]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [57]
V-type proton ATPase subunit H (ATP6V1H) OTX17GQ9 VATH_HUMAN Increases Expression [11]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Increases Response To Substance [58]
LYR motif-containing protein 9 (LYRM9) OT1MILTK LYRM9_HUMAN Affects Response To Substance [59]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Increases ADR [60]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [61]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [62]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Response To Substance [51]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Increases Response To Substance [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 95 DOT(s)
Indication(s) of Ifosfamide
Disease Entry ICD 11 Status REF
Adult central nervous system germ cell tumor N.A. Approved [9]
Adult teratoma N.A. Approved [9]
Advanced cancer 2A00-2F9Z Approved [9]
Extragonadal germ cell cancer N.A. Approved [9]
Extragonadal germ cell tumor N.A. Approved [9]
Kidney neoplasm N.A. Approved [9]
Solid tumour/cancer 2A00-2F9Z Approved [10]
Testicular germ cell tumor N.A. Approved [9]
Extragonadal nonseminomatous germ cell tumor N.A. Investigative [9]
Extragonadal seminoma N.A. Investigative [9]
Neuroblastoma 2D11.2 Investigative [9]
Retinoblastoma 2D02.2 Investigative [9]
Ifosfamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [64]
------------------------------------------------------------------------------------
Ifosfamide Interacts with 10 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [22]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [65]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [66]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [67]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [68]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [66]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [69]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [70]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [68]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
Ifosfamide Interacts with 214 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [71]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [71]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Ethylation [72]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Ethylation [72]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Affects Hydroxylation [65]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Response To Substance [73]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Response To Substance [73]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Response To Substance [74]
Beta-2-microglobulin (B2M) OTDWN6NX B2MG_HUMAN Increases Expression [75]
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Increases ADR [60]
Interleukin-19 (IL19) OT9VGDIP IL19_HUMAN Increases Secretion [76]
Solute carrier family 12 member 8 (SLC12A8) OTHJP5FU S12A8_HUMAN Decreases Expression [63]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [63]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [63]
Podocalyxin (PODXL) OTPNQXF3 PODXL_HUMAN Decreases Expression [63]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Increases Expression [63]
TRAF-type zinc finger domain-containing protein 1 (TRAFD1) OT7AU2R3 TRAD1_HUMAN Increases Expression [63]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [63]
Rho guanine nucleotide exchange factor 10 (ARHGEF10) OTHJ1Y4I ARHGA_HUMAN Affects Expression [63]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Decreases Expression [63]
Apoptosis regulatory protein Siva (SIVA1) OTDT0XZK SIVA_HUMAN Increases Expression [63]
Transcription factor MafG (MAFG) OTBQFUZH MAFG_HUMAN Increases Expression [63]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Increases Expression [63]
E3 ubiquitin-protein ligase SIAH2 (SIAH2) OTKED2XN SIAH2_HUMAN Increases Expression [63]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [63]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [63]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Affects Expression [63]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) OT6CLFXB MCAT_HUMAN Increases Expression [63]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [63]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Decreases Expression [63]
Mitochondrial import inner membrane translocase subunit Tim17-B (TIMM17B) OTSQGLSB TI17B_HUMAN Decreases Expression [63]
PR domain zinc finger protein 1 (PRDM1) OTQLSVBS PRDM1_HUMAN Decreases Expression [63]
E3 ubiquitin-protein ligase listerin (LTN1) OTIW2HTX LTN1_HUMAN Decreases Expression [63]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) OT1G9297 TFIP8_HUMAN Increases Expression [63]
Tetraspanin-12 (TSPAN12) OTF9I3CX TSN12_HUMAN Decreases Expression [63]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Increases Expression [63]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases Expression [63]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Expression [63]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [63]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [63]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [63]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [63]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Decreases Expression [63]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Decreases Expression [63]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Affects Expression [63]
Glycogen phosphorylase, liver form (PYGL) OTS1YFGR PYGL_HUMAN Decreases Expression [63]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [63]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [63]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [63]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Increases Expression [63]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [63]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [63]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Increases Expression [63]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases Expression [63]
Cation-independent mannose-6-phosphate receptor (IGF2R) OTDXPQVX MPRI_HUMAN Increases Expression [63]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) OTV04QE5 P4HA1_HUMAN Decreases Expression [63]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Increases Expression [63]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Decreases Expression [63]
Protein SON (SON) OT9VWV18 SON_HUMAN Decreases Expression [63]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [63]
Keratin, type I cytoskeletal 15 (KRT15) OTS6WLF7 K1C15_HUMAN Increases Expression [63]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [63]
Iduronate 2-sulfatase (IDS) OTZO94EO IDS_HUMAN Decreases Expression [63]
Ferrochelatase, mitochondrial (FECH) OTDWEI6C HEMH_HUMAN Decreases Expression [63]
Diacylglycerol kinase alpha (DGKA) OTTBVNEZ DGKA_HUMAN Increases Expression [63]
Thromboxane-A synthase (TBXAS1) OTAXZJJ4 THAS_HUMAN Increases Expression [63]
Bromodomain-containing protein 2 (BRD2) OTQP2MVJ BRD2_HUMAN Decreases Expression [63]
DnaJ homolog subfamily B member 2 (DNAJB2) OTZHPV5M DNJB2_HUMAN Increases Expression [63]
Neuropeptide Y receptor type 1 (NPY1R) OT5DA9DY NPY1R_HUMAN Increases Expression [63]
Threonine--tRNA ligase 1, cytoplasmic (TARS1) OT0PWST5 SYTC_HUMAN Decreases Expression [63]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Increases Expression [63]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Decreases Expression [63]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [63]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [63]
Pyrroline-5-carboxylate reductase 1, mitochondrial (PYCR1) OTQHB52T P5CR1_HUMAN Increases Expression [63]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Expression [63]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Decreases Expression [63]
Thrombospondin-2 (THBS2) OTXET551 TSP2_HUMAN Decreases Expression [63]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [63]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Affects Activity [63]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Affects Activity [63]
Transaldolase (TALDO1) OTDKV2S2 TALDO_HUMAN Increases Expression [63]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [63]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [63]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [63]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [63]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Increases Expression [63]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [63]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [63]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Decreases Expression [63]
NADP-dependent malic enzyme (ME1) OTSVEUQE MAOX_HUMAN Decreases Expression [63]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Decreases Expression [63]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [63]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [63]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Increases Expression [63]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Decreases Expression [63]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [63]
Dipeptidyl peptidase 1 (CTSC) OT79WJZZ CATC_HUMAN Increases Expression [63]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [63]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [63]
Homeobox protein DLX-1 (DLX1) OT7BH057 DLX1_HUMAN Decreases Expression [63]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [63]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Affects Expression [63]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [63]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [63]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [63]
Transmembrane protein 94 (TMEM94) OTT4ZSUA TMM94_HUMAN Decreases Expression [63]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Decreases Expression [63]
Zinc finger protein Rlf (RLF) OTCSPZVK RLF_HUMAN Increases Expression [63]
Peptidyl-prolyl cis-trans isomerase G (PPIG) OTZ8BTTM PPIG_HUMAN Decreases Expression [63]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [63]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Increases Expression [63]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [63]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Increases Expression [63]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Decreases Expression [63]
Protein disulfide-isomerase A5 (PDIA5) OT76ZSX5 PDIA5_HUMAN Increases Expression [63]
Condensin complex subunit 1 (NCAPD2) OT8VGE2O CND1_HUMAN Increases Expression [63]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3) OTWMKYD9 HERC3_HUMAN Decreases Expression [63]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Decreases Expression [63]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Increases Expression [63]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Activity [63]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [63]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Affects Expression [63]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Activity [63]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [63]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Increases Expression [63]
Atos homolog protein A (ATOSA) OTWFM5G0 ATOSA_HUMAN Decreases Expression [63]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [63]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [63]
RRP12-like protein (RRP12) OTQQAEH4 RRP12_HUMAN Increases Expression [63]
ALS2 C-terminal-like protein (ALS2CL) OT8RY7TZ AL2CL_HUMAN Affects Expression [63]
Dynamin-binding protein (DNMBP) OTMHH14H DNMBP_HUMAN Increases Expression [63]
Ribosomal protein eS27-like (RPS27L) OTZWHU0N RS27L_HUMAN Increases Expression [63]
Arginine/serine-rich coiled-coil protein 2 (RSRC2) OTLE0KQM RSRC2_HUMAN Decreases Expression [63]
Mitochondrial enolase superfamily member 1 (ENOSF1) OT65D3ZK ENOF1_HUMAN Decreases Expression [63]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Decreases Expression [63]
Protein LYRIC (MTDH) OTGH7N4C LYRIC_HUMAN Decreases Expression [63]
Liprin-beta-1 (PPFIBP1) OTRA2S7B LIPB1_HUMAN Increases Expression [63]
Dynein axonemal intermediate chain 3 (DNAI3) OTG1A0QP DNAI3_HUMAN Decreases Expression [63]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Decreases Expression [63]
Protein O-mannosyl-transferase TMTC2 (TMTC2) OTY1QWYU TMTC2_HUMAN Decreases Expression [63]
Ninein (NIN) OTVH3M4Z NIN_HUMAN Decreases Expression [63]
Ceramide synthase 5 (CERS5) OT5A2DNI CERS5_HUMAN Increases Expression [63]
Uncharacterized protein C8orf58 (C8ORF58) OTHW01L0 CH058_HUMAN Increases Expression [63]
F-box only protein 22 (FBXO22) OTEJ5MO0 FBX22_HUMAN Increases Expression [63]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Increases Expression [63]
F-box only protein 30 (FBXO30) OTD1P6LA FBX30_HUMAN Decreases Expression [63]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Decreases Expression [63]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Decreases Expression [63]
Uncharacterized protein C4orf3 (C4ORF3) OT6TFN1O CD003_HUMAN Decreases Expression [63]
Paraspeckle component 1 (PSPC1) OTYS6WQ8 PSPC1_HUMAN Decreases Expression [63]
Histone acetyltransferase KAT6B (KAT6B) OTMUDTAH KAT6B_HUMAN Decreases Expression [63]
E3 ubiquitin-protein ligase rififylin (RFFL) OT85MGDH RFFL_HUMAN Increases Expression [63]
Probable ATP-dependent RNA helicase DDX17 (DDX17) OTXRMMBP DDX17_HUMAN Decreases Expression [63]
GTP-binding protein Rit1 (RIT1) OTVNOGOH RIT1_HUMAN Increases Expression [63]
KICSTOR complex protein ITFG2 (ITFG2) OT0NLZ8I ITFG2_HUMAN Decreases Expression [63]
Protein TMEPAI (PMEPA1) OTY8Z9UF PMEPA_HUMAN Increases Expression [63]
Protein FAM162A (FAM162A) OT882DND F162A_HUMAN Decreases Expression [63]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [63]
SPRY domain-containing SOCS box protein 1 (SPSB1) OTGY26U4 SPSB1_HUMAN Increases Expression [63]
Carboxymethylenebutenolidase homolog (CMBL) OT8H3S3G CMBL_HUMAN Increases Expression [63]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Increases Expression [63]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [63]
ERO1-like protein alpha (ERO1A) OTVKOQWM ERO1A_HUMAN Increases Expression [63]
Protein FAM210B, mitochondrial (FAM210B) OT2QHEQ6 F210B_HUMAN Decreases Expression [63]
E1A-binding protein p400 (EP400) OTVQ75NX EP400_HUMAN Decreases Expression [63]
Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) OT9C3KFI KKCC2_HUMAN Increases Expression [63]
ETS-related transcription factor Elf-4 (ELF4) OT167PR5 ELF4_HUMAN Increases Expression [63]
Eukaryotic translation initiation factor 3 subunit C (EIF3C) OTR8RF9X EIF3C_HUMAN Decreases Expression [63]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [63]
Cancer-related nucleoside-triphosphatase (NTPCR) OTTRT6Z9 NTPCR_HUMAN Increases Expression [63]
G-protein coupled receptor 87 (GPR87) OTQX45UM GPR87_HUMAN Decreases Expression [63]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [63]
G protein-coupled receptor 88 (GPR88) OTGAT70V GPR88_HUMAN Increases Expression [63]
Coiled-coil domain-containing protein 90B, mitochondrial (CCDC90B) OTFFWB0C CC90B_HUMAN Decreases Expression [63]
Polyprenol reductase (SRD5A3) OT9IJLX7 PORED_HUMAN Decreases Expression [63]
E3 ubiquitin ligase RNF121 (RNF121) OTA0YMLW RN121_HUMAN Decreases Expression [63]
Ankyrin repeat family A protein 2 (ANKRA2) OTLSLV5A ANRA2_HUMAN Decreases Expression [63]
p53-induced death domain-containing protein 1 (PIDD1) OTWFM930 PIDD1_HUMAN Decreases Expression [63]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Increases Expression [63]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Increases Expression [63]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Increases Expression [63]
Dual specificity protein phosphatase 22 (DUSP22) OTEZ3U85 DUS22_HUMAN Increases Expression [63]
PAK4-inhibitor INKA2 (INKA2) OT9RA64U INKA2_HUMAN Increases Expression [63]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [63]
LIM and cysteine-rich domains protein 1 (LMCD1) OT3AWE8O LMCD1_HUMAN Decreases Expression [63]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2) OT8NJE5D SI1L2_HUMAN Decreases Expression [63]
Dolichol-phosphate mannosyltransferase subunit 3 (DPM3) OTSB4XO0 DPM3_HUMAN Increases Expression [63]
DnaJ homolog subfamily B member 9 (DNAJB9) OT38EQT6 DNJB9_HUMAN Increases Expression [63]
Mitochondrial fission process protein 1 (MTFP1) OT3L6F7U MTFP1_HUMAN Increases Expression [63]
SERTA domain-containing protein 1 (SERTAD1) OTBHKZQP SRTD1_HUMAN Increases Expression [63]
Oxidative stress-induced growth inhibitor 1 (OSGIN1) OT9KIVZW OSGI1_HUMAN Decreases Expression [63]
Heme transporter FLVCR2 (FLVCR2) OTAM94ID FLVC2_HUMAN Decreases Expression [63]
Exocyst complex component 7 (EXOC7) OT4YA137 EXOC7_HUMAN Increases Expression [63]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Affects Expression [63]
Lysine-specific demethylase 3A (KDM3A) OTZYJ8VN KDM3A_HUMAN Decreases Expression [63]
RNA polymerase II subunit A C-terminal domain phosphatase (CTDP1) OTHHFW17 CTDP1_HUMAN Decreases Expression [63]
Pleckstrin homology-like domain family A member 3 (PHLDA3) OTXFUDO2 PHLA3_HUMAN Increases Expression [63]
Insulin-induced gene 2 protein (INSIG2) OTX4VY51 INSI2_HUMAN Increases Expression [63]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [63]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Increases Expression [63]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [77]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [78]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [79]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Expression [78]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [77]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [78]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Decreases Activity [80]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [78]
Elastin (ELN) OTFSO7PG ELN_HUMAN Increases ADR [60]
S-adenosylmethionine decarboxylase proenzyme (AMD1) OTKAGZY3 DCAM_HUMAN Increases ADR [60]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [81]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases ADR [60]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Response To Substance [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 214 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC5K5Y7 HCT116 Investigative [1]
High grade ovarian serous adenocarcinoma DC70N9C OVCAR-5 Investigative [1]
Lung adenocarcinoma DCCNPLA HOP-62 Investigative [1]
Non-small cell lung carcinoma DCO2LBS HOP-92 Investigative [1]
Invasive ductal carcinoma DCZU18J HS 578T Investigative [82]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Imatinib FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
6 ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
7 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
8 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
9 Ifosfamide FDA Label
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
11 Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
12 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
13 Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004 Sep 1;101(5):979-88. doi: 10.1002/cncr.20457.
14 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
15 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
16 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
17 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
18 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
19 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
24 Drug Interactions Flockhart Table
25 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
26 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
27 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
28 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
29 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
30 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
31 Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-B inactivation. Toxicol In Vitro. 2012 Apr;26(3):396-405.
32 Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. PLoS One. 2011;6(9):e24831. doi: 10.1371/journal.pone.0024831. Epub 2011 Sep 14.
33 Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer. 2005 May 1;103(9):1800-9. doi: 10.1002/cncr.20973.
34 Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?. Clin Exp Immunol. 2008 Mar;151(3):391-8. doi: 10.1111/j.1365-2249.2007.03572.x. Epub 2008 Jan 10.
35 Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
36 Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
37 AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
38 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
39 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
40 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005 Feb 1;11(3):1336-41.
41 Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
42 Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget. 2015 Aug 21;6(24):20231-40. doi: 10.18632/oncotarget.4047.
43 Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
44 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
45 Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.
46 The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood. 2006 Nov 15;108(10):3538-47. doi: 10.1182/blood-2005-12-028456. Epub 2006 Jul 18.
47 Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia. Leukemia. 2003 Dec;17(12):2418-25. doi: 10.1038/sj.leu.2403152.
48 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
49 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
50 In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6.
51 Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol. 2007 May;78(5):417-31. doi: 10.1111/j.1600-0609.2007.00835.x.
52 The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
53 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022 Jul 15;365:11-23. doi: 10.1016/j.toxlet.2022.06.001. Epub 2022 Jun 6.
54 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
55 A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity. Toxicol Lett. 2022 Jun 15;363:11-26. doi: 10.1016/j.toxlet.2022.05.002. Epub 2022 May 18.
56 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
57 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
58 Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23.
59 Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
60 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
61 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
62 Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
63 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
64 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
65 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
66 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
67 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
68 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
69 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
70 A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
71 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
72 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
73 Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488-97. doi: 10.1093/toxsci/kfq154. Epub 2010 May 27.
74 Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998 Oct 1;58(19):4391-401.
75 A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15;76(12):2557-64. doi: 10.1002/1097-0142(19951215)76:12<2557::aid-cncr2820761223>3.0.co;2-9.
76 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
77 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
78 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
79 Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo. 1992 Mar-Apr;6(2):219-21.
80 Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998 Nov;65(3):238-45. doi: 10.1006/mgme.1998.2760.
81 Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol. 2005 Nov;27(11):582-9. doi: 10.1097/01.mph.0000187429.52616.8a.
82 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.